WUXI BIO(02269.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 2.44 billion, YoY increase of 4.3%
NewTimeSpace News: August 25, 2026, WUXI BIO(02269.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 11.79 billion, increased by 18.43% YoY; Net Profit stood at CNY 2.92 billion, YoY increase of 5.79%; Profit Attributable to Shareholders stood at CNY 2.44 billion, YoY increase of 4.3%; Basic Earnings Per Share (EPS) stood at CNY 0.6.
In terms of profitability, WUXI BIO Gross Profit changed from CNY 4.25 billion in the same period last year to CNY 5.45 billion in the current period, increased by CNY 1.2 billion; gross profit margin changed from 42.73% in the same period last year to 46.22% in the current period, increased by 3.49 percentage points; net profit changed from CNY 2.76 billion in the same period last year to CNY 2.92 billion in the current period, increased by CNY 159.6 million; net profit margin changed from 27.7% in the same period last year to 24.74% in the current period, decreased by 2.96 percentage points.
In terms of earnings quality, WUXI BIO Operating Profit changed from CNY 3.41 billion in the same period last year to CNY 3.46 billion in the current period, increased by CNY 52.21 million; Operating Profit Margin changed from 34.28% in the same period last year to 29.39% in the current period, decreased by 4.89 percentage points.
In terms of financial soundness, WUXI BIO Debt-to-Asset Ratio changed from 18.82% in the same period last year to 16.59% in the current period, decreased by 2.23 percentage points; Total Equity changed from CNY 49.065 billion in the same period last year to CNY 54.521 billion in the current period, increased by CNY 5.46 billion; Current Liabilities changed from CNY 8.49 billion in the same period last year to CNY 8.19 billion in the current period, decreased by CNY 297.19 million; Quick Ratio changed from 2.69 in the same period last year to 3.11 in the current period, increased by 0.42 percentage points.
In terms of R&D investment focus, WUXI BIO R&D Expenses changed from CNY 343.51 million in the same period last year to CNY 430.22 million in the current period, increased by CNY 86.71 million; R&D to Total Revenue Ratio changed from 3.45% in the same period last year to 3.65% in the current period, increased by 0.2 percentage points.
By the close of trading on August 25, 2026, WUXI BIO(02269) saw a gain of 7.41% in its share price, closing at HKD 52.2. The full-day turnover stood at HKD 3.06 billion, showing significant volume increase, with the latest market capitalization at HKD 216.37 billion.
NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
